The Federal Circuit recently held that makers of biosimilars must always notify brand-name rivals six months before commercial product launch. Brian Klock and Kathryn Easterling report.
08/03/2016 | Managing Intellectual Property Blog
Approval Biosimilar Notice Implicates Millions
1 min
Related Services
Related Insights
Identical Marks, Identical Types of Products: Not Enough to Presume Confusion
Identical Marks, Identical Types of Products: Not Enough to Presume Confusion
October 15, 2020
1min
Adapting to a ‘Normal’ Hybrid Trial During the Pandemic
Adapting to a ‘Normal’ Hybrid Trial During the Pandemic
October 12, 2020
1min
Spotlight On: Neulasta® (pegfilgrastim) / Fulphila® (pegfilgrastim-jmdb) / Udenyca® (pegfilgrastim-cbqv) / Ziextenzo® (pegfilgrastim-bmez) / Nyvepria™ (pegfilgrastim-apgf)
Spotlight On: Neulasta® (pegfilgrastim) / Fulphila® (pegfilgrastim-jmdb) / Udenyca® (pegfilgrastim-cbqv) / Ziextenzo® (pegfilgrastim-bmez) / Nyvepria™ (pegfilgrastim-apgf)
October 01, 2020
1min
Events
Virtual Post-Election Series
Virtual Post-Election Series
November 4-6, 2020 Venable LLP
ANA/BAA Marketing Law Conference 2020
ANA/BAA Marketing Law Conference 2020
November 10 - 12, 2020 ANA/BAA Marketing Law Conference
Recent News
Politico Pro Quotes Jim Burnley on the Potential Impact of Oregon Congressional Race on Infrastructure
Politico Pro Quotes Jim Burnley on the Potential Impact of Oregon Congressional Race on Infrastructure
October 23, 2020
1min
The Network Journal Recognizes JaMar Mancano Among Its 2019 40 Under Forty
The Network Journal Recognizes JaMar Mancano Among Its 2019 40 Under Forty
October 22, 2020
1min
Baltimore Business Journal Features Venable’s Diversity and Inclusion Initiatives
Baltimore Business Journal Features Venable’s Diversity and Inclusion Initiatives
October 20, 2020
1min